Short Sellers Run for Cover From Major Pharma

Photo of Chris Lange
By Chris Lange Updated Published
Short Sellers Run for Cover From Major Pharma

© Thinkstock

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.

The White House has promised reforms in the health care sector, such as changing the bidding process for drugs and shortening the FDA approval process. It has yet to be seen how much headway they can actually make with these reforms.

Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.

The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.

[nativounit]

Short interest in Pfizer Inc. (NYSE: PFE) decreased to 65.45 million shares from the previous 81.03 million. The stock was last seen trading at $35.15, within a 52-week range of $31.67 to $39.43.

The number of Merck & Co. Inc. (NYSE: MRK) shares short decreased to 20.40 million from 22.95 million in the previous period. Its shares were trading at $58.50, in a 52-week range of $52.83 to $66.41.

Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) short interest decreased to 53.78 million from the previous level of 55.84 million. Shares were trading at $19.25, in a 52-week range of $10.85 to $33.82.

Bristol-Myers Squibb Co. (NYSE: BMY) short interest decreased to 12.71 million shares from the previous reading of 14.32 million. Shares were last seen at $51.45, within a 52-week range of $49.96 to $70.05.

The number of shares short in AbbVie Inc. (NYSE: ABBV) increased to 18.77 million, compared to the previous 15.66 million. The stock was trading at $102.25, in a 52-week range of $64.61 to $125.86.

Eli Lilly and Co.’s (NYSE: LLY) short interest increased to 9.81 million shares from the previous 9.66 million. The stock was trading at $80.10. The 52-week range is $73.69 to $89.09.

[recirclink id=461737]

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Top Gaining Stocks

DELL Vol: 42,366,555
NTAP Vol: 15,911,807
NOW Vol: 68,243,561
IBM
IBM Vol: 28,527,546
HPE Vol: 86,996,387

Top Losing Stocks

CTRA Vol: 73,319,495
CLX Vol: 4,744,001
RMD Vol: 3,526,686
INTC Vol: 191,680,425
SWKS Vol: 5,407,806